INDUCE: A Prospective 2-Year Spine Registry

Conditions

• Degenerative Disc Disease (DDD)
• Subjects Treated With NMP as Part of Their Spine Surgery

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• NMP — DEVICE
  The study product is Induce Biologics NMP Fibers and NMP Micro Particulates however, this is observational research that involves standard of care. NMP is regulated as a human cellular or tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and in 21 CFR Part 1271. Under this regulation it did not require clinical evaluation before it could be used commercially. It is indicated for use "as a bone void filler for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the boney structure.

Study Details

The primary objective of this prospective, observational registry study is to evaluate the safety and effectiveness of Natural Matrix Protein® (NMP®) when used to promote fusion in the cervical or lumbar spine. The secondary objective is to assess patient reported outcomes following the use of NMP in the treatment of the spine.

Key Dates

Start date

Feb 17, 2026

Status verified

Apr 2026

Primary completion

Dec 31, 2028

Completion

Jan 31, 2029

Study Design

Enrollment

1,000 participants (estimated)

Arms

• Arm: Subjects treated on-label with NMP as part of their spine surgery.
  Subjects implanted on-label with NMP in at least one vertebral level in the cervical (C1-C7) or lumbar (L1-S1) spine as part of their surgery.

Primary Outcome Measure

Fusion [ Time Frame: 6 month and 12 month post surgery, and 24 month post surgery ]

Locations (2)

Find similar trials in Baton Rouge, LA

Related Studies

• HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
  Recruiting · ReGelTec, Inc. · Birmingham, Alabama